

IN THE CLAIMS:

Please amend the claims as follows:

1. (Currently Amended) A method for ~~prophylaxis or~~ treatment of breast cancer in a mammalian patient comprising administering to said patient a therapeutically effective amount of ~~one or more compound(s) selected from the group consisting of carbetocin and other long-acting oxytocin analogues~~ in a pharmaceutically acceptable carrier sufficient to inhibit ~~initiation or~~ growth of breast cancer in said patient.
2. (Cancelled)
3. (Currently Amended) The method of claim 1, wherein said ~~one or more oxytocin analogue(s) is/are~~ carbetocin is administered to said patient by a mode of administration selected from intramuscular, intravenous, intranasal, intrapulmonary, subcutaneous, parenteral, oral, or transdermal delivery.
4. (Currently Amended) The method of claim 3, wherein said ~~one or more oxytocin analogue(s) is/are~~ carbetocin is administered to said patent intranasally.
5. (Currently Amended) The method of claim 3, wherein said ~~one or more oxytocin analogue(s) is/are~~ carbetocin is formulated in said carrier for intranasal or intrapulmonary administration.
6. (Currently Amended) The method of claim 5, wherein said ~~one or more oxytocin analogue(s) is/are~~ carbetocin is formulated in a powder or aqueous formulation for intranasal delivery.
7. (Currently Amended) The method of claim 6, wherein said ~~one or more oxytocin analogue(s) is/are~~ carbetocin is combined in an aqueous formulation with one or more excipients selected from the group consisting of nonoxynol-9, laureth-9, poloxamer-124, octoxynol-9, lauramide DEA, chlorobutanol, glycerol, citric acid, sodium acetate for intranasal delivery.
8. (Original) The method of claim 6, wherein said carbetocin is formulated with a nonionic surfactant and polysorbate-80 in an aqueous formulation for intranasal delivery.
9. (Currently Amended) The method of claim 1, wherein said ~~one or more oxytocin analogue(s) is/are~~ carbetocin is administered in a dose of at least one microgram.
10. (Currently Amended) The method of claim 1, wherein said ~~one or more oxytocin analogue(s) is/are~~ carbetocin is administered daily in an intranasal formulation.

11. (Currently Amended) The method of claim 1, further comprising administering tamoxifen and/or raloxifene to said patient in an amount sufficient to inhibit ~~initiation or~~ growth of estrogen-dependent breast cancer in said patient.

12. (Currently Amended) The method of claim 11, wherein said ~~one or more oxytocin analogue(s) is/are~~ carbetocin and said tamoxifen and/or raloxifene are administered simultaneously as a mixture.

13. (Currently Amended) A method of ~~prophylaxis or~~ treatment of a ~~psychiatric~~ obsessive compulsive disorder in a mammalian patient comprising administering to said patient a therapeutically effective amount of ~~one or more compound(s) selected from the group consisting of~~ carbetocin ~~and other long-acting oxytocin analogues~~ in a pharmaceutically acceptable carrier sufficient to alleviate an obsessive-compulsive behavior ~~of said disorder~~ in said patient.

14. (Cancelled)

15. (Cancelled)

16. (Currently Amended) The method of claim 13, wherein said ~~one or more oxytocin analogue(s) is/are~~ carbetocin is administered to said patient by a mode of administration selected from intramuscular, intravenous, intranasal, intrapulmonary, subcutaneous, parenteral, oral, and transdermal delivery.

17. (Currently Amended) The method of claim 16, wherein said ~~one or more oxytocin analogue(s) is/are~~ carbetocin is administered to said patient intranasally.

18. (Currently Amended) The method of claim 16, wherein said ~~one or more oxytocin analogue(s) is/are~~ carbetocin is formulated in said carrier for intranasal or intrapulmonary administration.

19. (Currently Amended) The method of claim 18, wherein said ~~one or more oxytocin analogue(s) is/are~~ carbetocin is formulated in a powder or aqueous formulation for intranasal delivery.

20. (Currently Amended) The method of claim 19, wherein said ~~one or more oxytocin analogue(s) is/are~~ carbetocin is combined in an aqueous formulation with one or more excipients selected from the group consisting of nonoxynol-9, laureth-9, poloxamer-124, octoxynol-9, lauramide DEA, chlorobutanol, glycerol, citric acid, sodium phosphate, methyl paraben, propyl paraben, sorbitol, sodium chloride, and/or sodium acetate for intranasal delivery.

21. (Original) The method of claim 19, wherein said carbetocin is formulated with a nonionic surfactant and polysorbate-80 in an aqueous formulation for intranasal delivery.

22. (Currently Amended) The method of claim 13, wherein said ~~one or more oxytocin analogue(s) is/are~~ carbetocin is administered daily in an intranasal formulation.

23. (Currently Amended) The method of claim 13, wherein said ~~one or more oxytocin analogue(s) is/are~~ carbetocin is administered daily in an intranasal formulation.

24. (Original) The method of claim 13, further comprising administering a selective serotonin reuptake inhibitor or serotonin reuptake inhibitor to said patient in an amount sufficient to alleviate an obsessive-compulsive behavior in said patient.

25. (Currently Amended) The method of claim 24, wherein said ~~one or more oxytocin analogue(s) is/are~~ carbetocin and said selective serotonin reuptake inhibitor are administered simultaneously as a mixture.

26. (Currently Amended) A pharmaceutical composition for ~~prophylaxis or~~ treatment of breast cancer in a mammalian patient comprising a therapeutically effective amount of ~~one or more oxytocin analogue(s) selected from the group consisting of carbetocin and other long-acting oxytocin analogues~~ in a pharmaceutically acceptable carrier, wherein said composition is sufficient to inhibit ~~initiation or~~ growth of breast cancer in said patient.

27. (Cancelled)

28. (Currently Amended) The pharmaceutical composition of claim 26, wherein said ~~one or more oxytocin analogue(s) is/are~~ carbetocin is formulated in said carrier for intranasal or intrapulmonary administration.

29. (Currently Amended) The pharmaceutical composition of claim 26, wherein said ~~one or more oxytocin analogue(s) is/are~~ carbetocin is formulated in a powder or aqueous formulation for intranasal delivery.

30. (Currently Amended) The pharmaceutical composition of claim 26, wherein said ~~one or more oxytocin analogue(s) is/are~~ carbetocin is combined in an aqueous formulation with one or more excipients selected from the group consisting of nonoxynol-9, laureth-9, poloxamer-124, octoxynol-9, lauramide DEA, chlorobutanol, glycerol, citric acid, sodium phosphate, methyl paraben, propyl paraben, sorbitol, sodium chloride, and/or sodium acetate for intranasal delivery.

31. (Original) The pharmaceutical composition of claim 26, prepared in a unit dosage form containing at least one microgram of said one or more oxytocin analogue(s).

32. (Currently Amended) The pharmaceutical composition of claim 26, further comprising tamoxifen and/or raloxifen in an amount sufficient to inhibit ~~initiation or~~ growth of estrogen-dependent breast cancer in said patient.

33. (Currently Amended) A medicament suspension or powder for nasal administration to treat ~~or prevent~~ breast cancer comprising carbetocin and a powder of one or more cation exchange resins and/or one or more absorbent resins.

34. (Currently Amended) A pharmaceutical composition for ~~prophylaxis or~~ treatment of ~~a psychiatric~~ an obsessive compulsive disorder in a mammalian patient comprising a therapeutically effective amount of ~~one or more oxytocin analogue(s) selected from the group consisting of~~ carbetocin and ~~other long-acting oxytocin analogues~~ in a pharmaceutically acceptable carrier, wherein said composition is sufficient to alleviate at least one symptom of said ~~psychiatric~~ obsessive compulsive disorder in said patient.

35. (Cancelled)

36. (Currently Amended) The pharmaceutical composition of claim 34, wherein said ~~one or more oxytocin analogue(s) is/are~~ carbetocin is formulated in said carrier for intranasal or intrapulmonary administration.

37. (Currently Amended) The pharmaceutical composition of claim 34, wherein said ~~one or more oxytocin analogue(s) is/are~~ carbetocin is formulated in a powder or aqueous formulation for intranasal delivery.

38. (Original) The pharmaceutical composition of claim 34, further comprising a selective serotonin reuptake inhibitor or serotonin reuptake inhibitor.

39. (Currently Amended, Previously Added) A method for treatment of breast cancer in a mammalian patient comprising administering to said patient a therapeutically effective amount of ~~one or more compound(s) selected from the group consisting of~~ carbetocin and ~~other long-acting oxytocin analogues~~ in a pharmaceutically acceptable carrier sufficient to inhibit growth of breast cancer in said patient.

40. (Cancelled)

41. (Currently Amended) The method of claim 39, wherein said ~~one or more oxytocin analogue(s) is/are~~ carbetocin is administered to said patient by a mode of administration

selected from intramuscular, intravenous, intranasal, intrapulmonary, subcutaneous, parenteral, oral, or transdermal delivery.

42. (Currently Amended) The method of claim 41, wherein said ~~one or more oxytocin analogue(s) is/are~~ carbetocin is administered to said patient intranasally.

43. (Currently Amended) The method of claim 41, wherein said one or more oxytocin analogue(s) is/are formulated in said carrier for intranasal or intrapulmonary administration.

44. (Currently Amended) The method of claim 43, wherein said ~~one or more oxytocin analogue(s) is/are~~ carbetocin is formulated in a powder or aqueous formulation for intranasal delivery.

45. (Currently Amended) The method of claim 44, wherein said ~~one or more oxytocin analogue(s) is/are~~ carbetocin is combined in an aqueous formulation with one or more excipients selected from the group consisting of nonoxynol-9, laureth-9, poloxamer-124, octoxynol-9, lauramide DEA, chlorobutanol, glycerol, citric acid, sodium phosphate, methyl paraben, propyl paraben, sorbitol, sodium chloride, and/or sodium acetate for intranasal delivery.

46. (Previously Added) The method of claim 44, wherein said carbetocin is formulated with a nonionic surfactant and polysorbate-80 in an aqueous formulation for intranasal delivery.

47. (Currently Amended) The method of claim 39, wherein said ~~one or more oxytocin analogue(s) is/are~~ carbetocin is administered in a dose of at least one microgram.

48. (Currently Amended) The method of claim 39, wherein said ~~one or more oxytocin analogue(s) is/are~~ carbetocin is administered daily in an intranasal formulation.

49. (Previously Added) The method of claim 39, further comprising administering tamoxifen and/or raloxifen to said patient in an amount sufficient to inhibit growth of estrogen-dependent breast cancer in said patient.

50. (Currently Amended) The method of claim 49, wherein said ~~one or more oxytocin analogue(s) is/are~~ carbetocin and said tamoxifen and/or raloxifene are administered simultaneously as a mixture